Quarterly report pursuant to Section 13 or 15(d)

Note 6 - Inventory

v3.21.2
Note 6 - Inventory
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Inventory Disclosure [Text Block]

6.

Inventory

 

The components of inventory as of September 30, 2021 and December 31, 2020 are as follows:

 

 

   

September 30,

2021

   

December 31,

2020

 

Materials

  $ 77,750     $ 77,750  

Finished goods

    101,185       92,048  

Total inventory

  $ 178,935     $ 169,798  

 

During the three-month and nine-month periods ended September 30, 2021, we allocated approximately $0 and $10,000, respectively, of finished goods inventory for use in clinical trials. These transactions were recorded in research and development expense in the condensed consolidated statements of operations.